Gilead's HIV combination therapy succeeds in four late-stage studies
Reuters: Health News
(Reuters) - Gilead Sciences Inc said on Tuesday its combination treatment for HIV met the main goal in four late-stage studies, paving the way for regulatory submissions.
CBC | Health News
In an unprecedented move, Health Canada has cancelled its recall of children's jewelry sold by Canadian retailer Ardene after follow-up tests found the pieces don't actually contain excessive amounts of lead.
FOX News
In the first study of its kind, researchers have conducted a yearlong survey of the bacteria in a newly constructed hospital, starting two months before the facility opened and continuing over the next 10 months.
No comments:
Post a Comment